We write this for you, the tired, the weak and the weary, the dogged attendees of the South By South West festival in Austin this weekend. We know that you're exhausted, but it's not from the booze, the parties or the product pitches - it's the endless location based check-ins. If only someone had solved this in time, right?
From what we can tell, the folks over at Brightkite have the solution with Check.in, but have yet to release it to the achey-thumbed, smart-phoned masses.
According to the spl...
San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND) said today that its partner, GlaxoSmithKline, has won clearance to start marketing a new drug for a platelet deficiency in Europe. The treatment, eltrombopag (Revolade), is for patients for idiopathic thrombocytopenia purpura (ITP), a rare bleeding disorder in which the immune system attacks platelet cells that help people form clots. The drug, discovered by Ligand and developed by GSK, was approve...
Plenty of ink has been devoted over the years about how San Diegos biotech family tree can be traced back to Hybritech. The company was born in biotechs halcyon days in the 70s, and it quickly became the magnet for young scientific and business talent in San Diego. After Eli Lilly bought the place for more than $400 million in 1986, many of the young turks went on to plant seeds at new ventures all around San Diego and other biotech hubs around the wor...
Several years ago, I met a remarkable young man named Lucifer Chu in Shanghai. Chu had been the person who first translated the works of J.R.R. Tolkien into Chinese, after a considerable push to convince publishers that there was a market for fantasy and science fiction in China. He took the proceeds from the sales of the Lord of the Rings to launch a fantasy foundation, which promoted fantastical literature in Taiwan and mainland China, and he translated more than 30 fantasy novels for the Chinese market. ...